Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Food insecurity linked to tumor growth in pediatric neuroblastoma

2.

New imaging guidelines for head and neck cancers, a step toward practice change

3.

Rural residents continue to have higher odds of skin cancer, study finds

4.

24 months after radical prostateectomy, no PSA recurrence was observed when using apalutamide plus ADT.

5.

Is Exercise an Effective Treatment for Prostate Cancer?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot